NEO - ネオス・ファ―マシュ―ティカルズ （NeoGenomics Inc.）NEOのニュース
NeoGenomics, Inc.: NeoGenomics and German Breast Group Announce New Data Demonstrating Clinical Potential of the RaDaR MRD Assay in HR+/HER2- Breast Cancer 2023/06/05 11:02:00 Finanz Nachrichten
FT. MYERS, FL / ACCESSWIRE / June 5, 2023 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology testing and global contract research services, today announced new data in support of its …
NeoGenomics and German Breast Group Announce New Data Demonstrating Clinical Potential of the RaDaR MRD Assay in HR+/HER2- Breast Cancer 2023/06/05 11:00:00 Accesswire
FT. MYERS, FL / ACCESSWIRE / June 5, 2023 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology testing and global contract research services, today announced new data in support of its RaDaR® assay for the detection of molecular residual disease (MRD) and recurrence in patients with high-risk hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer. Data from a retrospective analysis of the Phase 3 PENELOPE-B study was presented in part at the 2023 ASCO® Annual Meeting on Friday, June 2 nd in Chicago, IL. In collaboration with the trial sponsor, German Breast Group (GBG), the study used NeoGenomics'' RaDaR personalized MRD assay to assess the potential of circulating tumor DNA (ctDNA) analysis to predict future clinical relapse of patients enrolled in the PENELOPE-B trial. " We are delighted that the development of liquid biopsies for the early detection of circulating tumor DNA is moving forward. There is an unmet need for early response evaluation in plenty of clinical situations, and these results support the potential benefits of the clinical utility of individualized assays, such as the RaDaR assay." said Professor Sibylle Loibl, MD, Chief Executive Officer of German Breast Group. "Prognostic and predictive implications of circulating tumor DNA assays still need to be validated on a broader basis.
NeoGenomics, Inc.: NeoGenomics to Participate at the Goldman Sachs 44th Annual Global Healthcare Conference 2023/06/01 11:02:00 Finanz Nachrichten
FT MYERS, FL / ACCESSWIRE / June 1, 2023 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing services and global oncology contract research services, today announ…
NeoGenomics to Participate at the Goldman Sachs 44th Annual Global Healthcare Conference 2023/06/01 11:00:00 Accesswire
FT MYERS, FL / ACCESSWIRE / June 1, 2023 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing services and global oncology contract research services, today announced the company will be participating in the upcoming Goldman Sachs 44 th Annual Global Healthcare Conference in Dana Point, California. NeoGenomics'' management is scheduled to participate in a fireside chat on Wednesday, June 14 th at 11:20 a.m. Pacific Time/2:20 p.m. Eastern Time. A live and archived audio webcast of the presentation will be available on the "News, Events, and Webcasts" tab via the Investor Relations section of the Company''s website at ir.neogenomics.com . About NeoGenomics, Inc. NeoGenomics, Inc. specializes in cancer genetics testing and information services, providing one of the most comprehensive oncology-focused testing menus in the world for physicians to help them diagnose and treat cancer. The Company''s Pharma Services Division serves pharmaceutical clients in clinical trials and drug development.
NeoGenomics, Inc.: NeoGenomics to Showcase the Transformational Impact of RaDaR Assay for Molecular Residual Disease and Recurrence Monitoring at ASCO 2023/05/30 11:02:00 Finanz Nachrichten
FT. MYERS, FL / ACCESSWIRE / May 30, 2023 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology testing and global contract research services, today announced new data supporting its can…
NeoGenomics, Inc.: NeoGenomics and German Breast Group Announce New Data Demonstrating Clinical Potential of the RaDaR MRD Assay in HR+/HER2- Breast Cancer 2023/06/05 11:02:00 Finanz Nachrichten
FT. MYERS, FL / ACCESSWIRE / June 5, 2023 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology testing and global contract research services, today announced new data in support of its …
NeoGenomics and German Breast Group Announce New Data Demonstrating Clinical Potential of the RaDaR MRD Assay in HR+/HER2- Breast Cancer 2023/06/05 11:00:00 Accesswire
FT. MYERS, FL / ACCESSWIRE / June 5, 2023 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology testing and global contract research services, today announced new data in support of its RaDaR® assay for the detection of molecular residual disease (MRD) and recurrence in patients with high-risk hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer. Data from a retrospective analysis of the Phase 3 PENELOPE-B study was presented in part at the 2023 ASCO® Annual Meeting on Friday, June 2 nd in Chicago, IL. In collaboration with the trial sponsor, German Breast Group (GBG), the study used NeoGenomics'' RaDaR personalized MRD assay to assess the potential of circulating tumor DNA (ctDNA) analysis to predict future clinical relapse of patients enrolled in the PENELOPE-B trial. " We are delighted that the development of liquid biopsies for the early detection of circulating tumor DNA is moving forward. There is an unmet need for early response evaluation in plenty of clinical situations, and these results support the potential benefits of the clinical utility of individualized assays, such as the RaDaR assay." said Professor Sibylle Loibl, MD, Chief Executive Officer of German Breast Group. "Prognostic and predictive implications of circulating tumor DNA assays still need to be validated on a broader basis.
NeoGenomics, Inc.: NeoGenomics to Participate at the Goldman Sachs 44th Annual Global Healthcare Conference 2023/06/01 11:02:00 Finanz Nachrichten
FT MYERS, FL / ACCESSWIRE / June 1, 2023 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing services and global oncology contract research services, today announ…
NeoGenomics to Participate at the Goldman Sachs 44th Annual Global Healthcare Conference 2023/06/01 11:00:00 Accesswire
FT MYERS, FL / ACCESSWIRE / June 1, 2023 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing services and global oncology contract research services, today announced the company will be participating in the upcoming Goldman Sachs 44 th Annual Global Healthcare Conference in Dana Point, California. NeoGenomics'' management is scheduled to participate in a fireside chat on Wednesday, June 14 th at 11:20 a.m. Pacific Time/2:20 p.m. Eastern Time. A live and archived audio webcast of the presentation will be available on the "News, Events, and Webcasts" tab via the Investor Relations section of the Company''s website at ir.neogenomics.com . About NeoGenomics, Inc. NeoGenomics, Inc. specializes in cancer genetics testing and information services, providing one of the most comprehensive oncology-focused testing menus in the world for physicians to help them diagnose and treat cancer. The Company''s Pharma Services Division serves pharmaceutical clients in clinical trials and drug development.
NeoGenomics, Inc.: NeoGenomics to Showcase the Transformational Impact of RaDaR Assay for Molecular Residual Disease and Recurrence Monitoring at ASCO 2023/05/30 11:02:00 Finanz Nachrichten
FT. MYERS, FL / ACCESSWIRE / May 30, 2023 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology testing and global contract research services, today announced new data supporting its can…
NeoGenomics Inc. (NEO) did well last session? 2023/03/07 16:40:00 US Post News
In Monday’s session, NeoGenomics Inc. (NASDAQ:NEO) marked $17.51 per share, down from $17.99 in the previous session. While NeoGenomics Inc. has underperformed by -2.67%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, NEO fell by -13.83%, with highs and lows ranging from $20.78 to $6.00, whereas […]
Neogenomics: At A Key Inflection Point In Growth Route (NASDAQ:NEO) 2023/03/03 08:55:59 Seeking Alpha
NeoGenomics'' profitability and return on capital are a concern, so FY23 will be the key year to evidence the success of the new strategy. Find out why NEO stock is a Hold.
NeoGenomics upgraded to buy at Benchmark on performance improvement program (NASDAQ:NEO) 2023/02/24 15:57:43 Seeking Alpha
Benchmark has upgraded NeoGenomics (NEO) to buy from hold noting that a management performance improvement program is poised to deliver profitability.